6th Jun 2023 13:36
Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results. Read More
